BMS-833923
- Generic Name
- BMS-833923
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H27N5O
- CAS Number
- 1059734-66-5
- Unique Ingredient Identifier
- 41J7ZJ239R
- Associated Conditions
- -
- Associated Therapies
- -
Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 2
- Registration Number
- NCT02100371
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01357655
- Locations
- 🇺🇸
Tennessee Oncology Pllc, Nashville, Tennessee, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT01218477
- Locations
- 🇺🇸
University Of California Medical Center, San Francisco, California, United States
🇺🇸Ut M.D. Anderson Cancer Center, Houston, Texas, United States
🇬🇧Local Institution, Glasgow, United Kingdom
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT00927875
- Locations
- 🇮🇪
Local Institution, Dublin, Ireland
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT00909402
- Locations
- 🇳🇱
Local Institution, Amsterdam, Netherlands
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT00884546
- Locations
- 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.